🚀 VC round data is live in beta, check it out!
Entera Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Entera Bio and similar public comparables like LTR Pharma, Grace Therapeutics, Dicot Pharma, Türk İlaç and more.
Entera Bio Overview
About Entera Bio
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Founded
2009
HQ
Employees
20
Website
Sectors
Financials (LTM)
EV
$55M
Entera Bio Financials
Entera Bio reported last 12-month revenue of $42K.
In the same LTM period, Entera Bio generated had net loss of ($17M).
Revenue (LTM)
Entera Bio P&L
In the most recent fiscal year, Entera Bio reported revenue of $181K and EBITDA of ($10M).
Entera Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $42K | XXX | $181K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $9K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 5% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($10M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (5270%) | XXX | XXX | XXX |
| EBIT Margin | (41377%) | XXX | (5296%) | XXX | XXX | XXX |
| Net Profit | ($17M) | XXX | ($10M) | XXX | XXX | XXX |
| Net Margin | (41258%) | XXX | (5271%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Entera Bio Stock Performance
Entera Bio has current market cap of $63M, and enterprise value of $55M.
Market Cap Evolution
Entera Bio's stock price is $1.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55M | $63M | 0.0% | XXX | XXX | XXX | $-0.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEntera Bio Valuation Multiples
Entera Bio trades at 1307.6x EV/Revenue multiple, and (5.8x) EV/EBITDA.
EV / Revenue (LTM)
Entera Bio Financial Valuation Multiples
As of March 21, 2026, Entera Bio has market cap of $63M and EV of $55M.
Equity research analysts estimate Entera Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Entera Bio has a P/E ratio of (3.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $63M | XXX | $63M | XXX | XXX | XXX |
| EV (current) | $55M | XXX | $55M | XXX | XXX | XXX |
| EV/Revenue | 1307.6x | XXX | 303.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.8x) | XXX | XXX | XXX |
| EV/EBIT | (3.2x) | XXX | (5.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 6102.2x | XXX | XXX | XXX |
| P/E | (3.7x) | XXX | (6.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Entera Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Entera Bio Margins & Growth Rates
Entera Bio's revenue in the last fiscal year declined by (77%).
Entera Bio's revenue per employee in the last FY averaged $0.0M.
Entera Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (77%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (5270%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 8% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 15318% | XXX | 2815% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 26059% | XXX | 2486% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 5301% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Entera Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Grace Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dicot Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Türk İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Q32 Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Entera Bio M&A Activity
Entera Bio acquired XXX companies to date.
Last acquisition by Entera Bio was on XXXXXXXX, XXXXX. Entera Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Entera Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEntera Bio Investment Activity
Entera Bio invested in XXX companies to date.
Entera Bio made its latest investment on XXXXXXXX, XXXXX. Entera Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Entera Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Entera Bio
| When was Entera Bio founded? | Entera Bio was founded in 2009. |
| Where is Entera Bio headquartered? | Entera Bio is headquartered in United States. |
| How many employees does Entera Bio have? | As of today, Entera Bio has over 20 employees. |
| Who is the CEO of Entera Bio? | Entera Bio's CEO is Miranda Jayne Toledano. |
| Is Entera Bio publicly listed? | Yes, Entera Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Entera Bio? | Entera Bio trades under ENTX ticker. |
| When did Entera Bio go public? | Entera Bio went public in 2018. |
| Who are competitors of Entera Bio? | Entera Bio main competitors are LTR Pharma, Grace Therapeutics, Dicot Pharma, Türk İlaç. |
| What is the current market cap of Entera Bio? | Entera Bio's current market cap is $63M. |
| What is the current revenue of Entera Bio? | Entera Bio's last 12 months revenue is $42K. |
| What is the current revenue growth of Entera Bio? | Entera Bio revenue growth (vs. last FY) is (77%). |
| What is the current EV/Revenue multiple of Entera Bio? | Current revenue multiple of Entera Bio is 1307.6x. |
| Is Entera Bio profitable? | No, Entera Bio is not profitable. |
| What is the current net income of Entera Bio? | Entera Bio's last 12 months net income is ($17M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.